AR032743A1 - Composiciones y metodos para la terapia y el diagnostico de cancer de pulmon - Google Patents

Composiciones y metodos para la terapia y el diagnostico de cancer de pulmon

Info

Publication number
AR032743A1
AR032743A1 ARP000103352A ARP000103352A AR032743A1 AR 032743 A1 AR032743 A1 AR 032743A1 AR P000103352 A ARP000103352 A AR P000103352A AR P000103352 A ARP000103352 A AR P000103352A AR 032743 A1 AR032743 A1 AR 032743A1
Authority
AR
Argentina
Prior art keywords
compositions
cancer
methods
diagnosis
therapy
Prior art date
Application number
ARP000103352A
Other languages
English (en)
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/476,300 external-priority patent/US20030125245A1/en
Priority claimed from US09/589,184 external-priority patent/US6686447B1/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of AR032743A1 publication Critical patent/AR032743A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Composiciones y métodos para la terapia y el diagnostico del cáncer, por ejemplo del cáncer de pulmon. Las composiciones pueden comprender una o más proteínas de tumor de pulmon, porciones inmunogénicas de las mismas, o polinucleotidos que codifican dichas porciones. Como alternativa, una composicion terapéutica puede comprender una célula que comprende un antígeno que expresa una proteína de tumor de pulmon, una célula T que es específica para la células que expresan dicha proteína. Las composiciones se pueden usar, por ejemplo, para la prevencion y tratamiento de enfermedades tales como el cáncer de pulmon. También se proveen métodos de diagnostico basados en la deteccion de una proteína de tumor de pulmon, o RNAm que codifica dicha proteína en una muestra.
ARP000103352A 1999-06-30 2000-06-30 Composiciones y metodos para la terapia y el diagnostico de cancer de pulmon AR032743A1 (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US34649299A 1999-06-30 1999-06-30
US41935699A 1999-10-15 1999-10-15
US46686799A 1999-12-17 1999-12-17
US09/476,300 US20030125245A1 (en) 1999-06-30 1999-12-30 Compositions and methods for therapy and diagnosis of lung cancer
US09/519,642 US6933363B1 (en) 1999-06-30 2000-03-06 Compositions and methods for therapy and diagnosis of lung cancer
US53307700A 2000-03-22 2000-03-22
US54625900A 2000-04-10 2000-04-10
US56040600A 2000-04-27 2000-04-27
US09/589,184 US6686447B1 (en) 1999-06-30 2000-06-05 Compositions and methods for the therapy and diagnosis of lung cancer

Publications (1)

Publication Number Publication Date
AR032743A1 true AR032743A1 (es) 2003-11-26

Family

ID=27578819

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103352A AR032743A1 (es) 1999-06-30 2000-06-30 Composiciones y metodos para la terapia y el diagnostico de cancer de pulmon

Country Status (15)

Country Link
US (1) US6630574B1 (es)
EP (1) EP1196565A2 (es)
JP (1) JP2004500029A (es)
CN (1) CN1367829A (es)
AR (1) AR032743A1 (es)
AU (1) AU769143B2 (es)
BR (1) BR0012069A (es)
CA (1) CA2380873A1 (es)
CZ (1) CZ20014718A3 (es)
HU (1) HUP0201757A3 (es)
MX (1) MXPA02000192A (es)
NO (1) NO20016427L (es)
NZ (1) NZ516381A (es)
PL (1) PL354093A1 (es)
WO (1) WO2001000828A2 (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000690A2 (en) * 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20060084082A1 (en) * 1997-03-07 2006-04-20 Human Genome Sciences, Inc. 186 human secreted proteins
US20020172952A1 (en) * 1999-06-30 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030211510A1 (en) * 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030170255A1 (en) * 1999-06-30 2003-09-11 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2001029088A1 (en) * 1999-10-19 2001-04-26 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
US6902890B1 (en) 1999-11-04 2005-06-07 Diadexus, Inc. Method of diagnosing monitoring, staging, imaging and treating cancer
WO2001036644A2 (en) * 1999-11-18 2001-05-25 Curagen Corporation Wnt-regulated cytokine-like polypeptide and nucleic acids encoding same
US7005499B1 (en) * 1999-11-18 2006-02-28 Genentech, Inc. Wnt-regulated cytokine-like polypeptide and nucleic acids encoding same
US20020038012A1 (en) * 2000-02-22 2002-03-28 Gregory Donoho Novel human regulatory protein and polynucleotides encoding the same
NZ520967A (en) * 2000-02-25 2004-04-30 Oxford Glycosciences Uk Ltd Use of breast cancer associated membrane proteins (BCMP) for treatment, prophylaxis and diagnosis of breast cancer
US20030143654A1 (en) * 2000-05-12 2003-07-31 Matthias Grell F-box containing protein
AR031250A1 (es) * 2000-07-11 2003-09-17 Corixa Corp Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
AU2001287004A1 (en) * 2000-09-01 2002-03-13 Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services Xage-1, a gene expressed in multiple cancers, and uses thereof
US20060063230A1 (en) 2000-12-27 2006-03-23 Roman Naworth Sulfatases and methods of use thereof
US20040121309A1 (en) 2002-12-06 2004-06-24 Ecker David J. Methods for rapid detection and identification of bioagents in blood, bodily fluids, and bodily tissues
US7226739B2 (en) 2001-03-02 2007-06-05 Isis Pharmaceuticals, Inc Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations
WO2004060278A2 (en) 2002-12-06 2004-07-22 Isis Pharmaceuticals, Inc. Methods for rapid identification of pathogens in humans and animals
US20030027135A1 (en) 2001-03-02 2003-02-06 Ecker David J. Method for rapid detection and identification of bioagents
US7666588B2 (en) 2001-03-02 2010-02-23 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
EP1516049A4 (en) * 2001-05-11 2006-01-11 Corixa Corp COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF LUNG CANCER
EP1270732A1 (en) * 2001-06-21 2003-01-02 Schuler, Gerold Improved transfection of eukaryontic cells with linear polynucleotides by electroporation
US8073627B2 (en) 2001-06-26 2011-12-06 Ibis Biosciences, Inc. System for indentification of pathogens
US7217510B2 (en) 2001-06-26 2007-05-15 Isis Pharmaceuticals, Inc. Methods for providing bacterial bioagent characterizing information
AU2002356522A1 (en) * 2001-09-04 2003-04-07 Bristol-Myers Squibb Company Polynucleotide encoding adapter protein, pmn29
WO2003046165A1 (en) * 2001-11-26 2003-06-05 Bayer Healthcare Ag Regulation of human aldose reductase-like protein
US8046171B2 (en) 2003-04-18 2011-10-25 Ibis Biosciences, Inc. Methods and apparatus for genetic evaluation
US8057993B2 (en) 2003-04-26 2011-11-15 Ibis Biosciences, Inc. Methods for identification of coronaviruses
US8158354B2 (en) 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US7964343B2 (en) 2003-05-13 2011-06-21 Ibis Biosciences, Inc. Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
ATE528397T1 (de) 2003-08-08 2011-10-15 Perseus Proteomics Inc Bei krebs überexprimiertes gen
US7087733B2 (en) * 2003-09-02 2006-08-08 Ken-Shwo Dai Human ARL-related gene variants associated with cancers
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8242254B2 (en) 2003-09-11 2012-08-14 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8163895B2 (en) 2003-12-05 2012-04-24 Ibis Biosciences, Inc. Compositions for use in identification of orthopoxviruses
US7666592B2 (en) 2004-02-18 2010-02-23 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US8119336B2 (en) 2004-03-03 2012-02-21 Ibis Biosciences, Inc. Compositions for use in identification of alphaviruses
US8940488B2 (en) 2004-03-31 2015-01-27 Hiroyuki Aburatani Cancer diagnosis and treatment of cancer using anti-robo 1 antibody
CN101014860B (zh) 2004-03-31 2012-01-25 中外制药株式会社 抗-robo1抗体用于制备癌症治疗药物及相关诊断试剂盒
JP4810533B2 (ja) 2004-05-24 2011-11-09 アイビス バイオサイエンシズ インコーポレイティッド ディジタルスレショルド化による選択的イオン濾過作用を用いた質量分光測定法
US20050266411A1 (en) 2004-05-25 2005-12-01 Hofstadler Steven A Methods for rapid forensic analysis of mitochondrial DNA
US7811753B2 (en) 2004-07-14 2010-10-12 Ibis Biosciences, Inc. Methods for repairing degraded DNA
WO2006062917A2 (en) * 2004-12-06 2006-06-15 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as cancer vaccine adjuvants
CA2600184A1 (en) 2005-03-03 2006-09-08 Isis Pharmaceuticals, Inc. Compositions for use in identification of adventitious viruses
US8084207B2 (en) 2005-03-03 2011-12-27 Ibis Bioscience, Inc. Compositions for use in identification of papillomavirus
US8026084B2 (en) 2005-07-21 2011-09-27 Ibis Biosciences, Inc. Methods for rapid identification and quantitation of nucleic acid variants
US7943295B2 (en) * 2005-07-29 2011-05-17 Oncotherapy Science, Inc. Screening and therapeutic method for NSCLC targeting CDCA1-KNTC2 complex
EP2064332B1 (en) 2006-09-14 2012-07-18 Ibis Biosciences, Inc. Targeted whole genome amplification method for identification of pathogens
WO2008104002A2 (en) 2007-02-23 2008-08-28 Ibis Biosciences, Inc. Methods for rapid forensic dna analysis
JP5117765B2 (ja) 2007-05-28 2013-01-16 国立大学法人 東京大学 抗ｒｏｂｏ１抗体を含むｐｅｔ用腫瘍診断剤
WO2008151023A2 (en) 2007-06-01 2008-12-11 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
CN101835892B (zh) 2007-08-20 2013-11-06 肿瘤疗法科学股份有限公司 Cdca1肽和包含cdca1肽的药剂
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
WO2010033627A2 (en) 2008-09-16 2010-03-25 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US8534447B2 (en) 2008-09-16 2013-09-17 Ibis Biosciences, Inc. Microplate handling systems and related computer program products and methods
WO2010033599A2 (en) 2008-09-16 2010-03-25 Ibis Biosciences, Inc. Mixing cartridges, mixing stations, and related kits, systems, and methods
US8158936B2 (en) 2009-02-12 2012-04-17 Ibis Biosciences, Inc. Ionization probe assemblies
WO2011008972A1 (en) 2009-07-17 2011-01-20 Ibis Biosciences, Inc. Systems for bioagent identification
US8950604B2 (en) 2009-07-17 2015-02-10 Ibis Biosciences, Inc. Lift and mount apparatus
US9890408B2 (en) 2009-10-15 2018-02-13 Ibis Biosciences, Inc. Multiple displacement amplification
NL2007536C2 (en) 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.
IN2014DN10991A (es) * 2012-05-25 2015-09-25 Cellectis
CN103212077B (zh) * 2013-04-09 2015-09-23 梅林� Erbin抑制剂在制备抗肿瘤药物中的应用
EP3090059B1 (en) * 2014-01-05 2018-06-06 Biomirna Holdings Ltd. Lung cancer determinations using mirna ratios
WO2022246204A2 (en) * 2021-05-21 2022-11-24 Ionis Pharmaceuticals, Inc. Compounds for reducing ptbp1 expression

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0246709A1 (en) * 1986-05-20 1987-11-25 Stichting Katholieke Universiteit Recombinant DNA and cDNA, mRNA, protein, antibodies, and a method of detecting tumor cells
US5589579A (en) * 1994-07-19 1996-12-31 Cytoclonal Pharmaceutics, Inc. Gene sequence and probe for a marker of non-small cell lung carinoma
US20020165378A1 (en) * 1996-03-15 2002-11-07 Seishi Kato Human membrane antigen tm4 superfamily protein and dna encoding this protein
US5776683A (en) * 1996-07-11 1998-07-07 California Pacific Medical Center Methods for identifying genes amplified in cancer cells
US6653445B1 (en) * 1997-01-21 2003-11-25 Human Genome Sciences, Inc. Human CCV polypeptides
US6146877A (en) * 1997-03-21 2000-11-14 The Trustees Of Columbia University In The City Of New York Identification of the progression elevated gene-3 and uses thereof
CA2306777A1 (en) 1997-10-22 1999-04-29 Helix Research Institute Method for screening full-length cdna clones
ID27813A (id) 1998-01-28 2001-04-26 Corixa Corp Senyawa-senyawa untuk terapi dan diagnosa kanker paru-paru dan metoda untuk penggunaannya
WO2000021990A1 (en) 1998-10-15 2000-04-20 Genetics Institute, Inc. SECRETED EXPRESSED SEQUENCE TAGS (sESTs)
DE69938190T2 (de) 1998-10-15 2009-03-05 Novartis Vaccines and Diagnostics, Inc., Emeryville Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
WO2000055375A1 (en) 1999-03-17 2000-09-21 Alphagene, Inc. Secreted proteins and polynucleotides encoding them
CA2382165A1 (en) 1999-12-08 2001-06-14 Genset S.A. Full-length human cdnas encoding potentially secreted proteins

Also Published As

Publication number Publication date
US6630574B1 (en) 2003-10-07
EP1196565A2 (en) 2002-04-17
NO20016427D0 (no) 2001-12-28
PL354093A1 (en) 2003-12-29
JP2004500029A (ja) 2004-01-08
HUP0201757A2 (en) 2002-09-28
WO2001000828A3 (en) 2001-08-02
CZ20014718A3 (cs) 2003-01-15
NO20016427L (no) 2002-02-25
AU769143B2 (en) 2004-01-15
AU5902700A (en) 2001-01-31
CN1367829A (zh) 2002-09-04
WO2001000828A2 (en) 2001-01-04
BR0012069A (pt) 2002-08-27
MXPA02000192A (es) 2004-08-12
NZ516381A (en) 2004-03-26
HUP0201757A3 (en) 2010-01-28
CA2380873A1 (en) 2001-01-04

Similar Documents

Publication Publication Date Title
AR032743A1 (es) Composiciones y metodos para la terapia y el diagnostico de cancer de pulmon
WO2001040269A3 (en) Compositions and methods for therapy and diagnosis of breast cancer
WO2001096388A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001096390A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2000060076A3 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
DE60126592D1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
WO2001025272A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
WO2001079286A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2001034802A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
BR9912007A (pt) Composições e métodos para terapia e diagnóstico de câncer de próstata
AR031250A1 (es) Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
EP1767636A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2001073027A3 (en) Compositions and methods for therapy and diagnosis of colon cancer
WO2001049716A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
AR029547A1 (es) Composiciones y metodos para la terapia y el diagnostico de cancer de pulmon
AR029540A1 (es) COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
WO2000078960A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2001057207A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2001073031A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2001096389A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
DE60139150D1 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs
WO2002045657A3 (en) Ovarian tumor antigen and methods of use therefor
WO2002012332A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001090154A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer

Legal Events

Date Code Title Description
FB Suspension of granting procedure